Hansa Medical AB establishes a US medical advisory board for IdeS in kidney transplantation

Hansa Medical AB today announced the inception of a US medical advisory board
for IdeS in kidney transplantation. The board will assist the company in
developing IdeS within transplantation in sensitized patients.
Hansa Medical AB has previously initiated a similar European advisory board with
leading transplantation experts in Europe. The US medical advisory board will be
valuable to the further development of IdeS. The two boards are connected
through the joint board member, Professor Kathryn Wood, Oxford, UK.

Dr Stanley Jordan
Dr Stanley Jordan, MD, the chairman of the US advisory board.
Dr Stanley Jordan is a Director of Kidney Transplantation and Transplant
Immunology, Kidney and Pancreas Transplant Center and Director of Division of
Pediatric and Adult Nephrology at Cedars Sinai Medical Center, Los Angeles, USA.
Dr Jordan's focus is on immunology and transplantation. He has performed
extensive research funded by dozens of research grants and awards, including
National Institutes of Health controlled clinical trials in kidney
transplantation.

Dr Jordan has written hundreds of articles in scientific journals and authored
about two dozen book chapters. He was appointed by the National Institutes of
Health's National Institute of Allergy and Infectious Diseases to advise
Congress on the safety and efficacy of intravenous gammaglobulin products. Dr.
Jordan has been principal investigator on 3 NIH Controlled Clinical Trials in
Kidney Transplantation. Dr. Jordan has received the Medical Sciences Award from
the UCLA Alumni Association, Gift of Life Award from the National Kidney
Foundation, Established Investigator Award from the American Society of
Transplantation and Distinguished Alumni Award from the University of North
Carolina-Chapel Hill School of Medicine. Dr. Jordan is a member of national and
international professional societies and has served on the editorial boards of
numerous professional journals.

Dr. Robert A. Montgomery
Dr. Robert A. Montgomery, MD, DPhil, FACS is the Chief of the Division of
Transplantation, Professor of Surgery, and the Director Comprehensive
Transplant Center at Johns Hopkins, Baltimore, Maryland. Dr. Robert A.
Montgomery is the inaugural recipient of the Margery K. and Thomas Pozefsky
Endowed Professorship in Kidney Transplantation.

Dr. Montgomery was part of the team that developed the laparoscopic procedure
for live kidney donation, a procedure that has become the standard throughout
the world.

Dr. Montgomery is considered a world expert on kidney transplantation for highly
sensitized and ABO incompatible patients. Dr. Montgomery has received important
awards and distinctions including a Fulbright Scholarship, a Thomas J. Watson
Fellowship and memberships in the Phi Beta Kappa and Alpha Omega Alpha academic
honor societies. He has been awarded multiple scholarships from The American
College of Surgeons and The American Society of Transplant Surgeons. The
National Kidney Foundation of Maryland has recognized his contributions to the
field of transplantation with the Champion of Hope Award and the National Kidney
Registry recognized him with the Terasaki Medical Innovation Award.

Professor Kathryn Wood
Kathryn Wood is Professor of Immunology in the Nuffield Department of Surgical
Sciences, University of Oxford, where she runs the Transplantation Research
Immunology Group. Her research focuses on tolerance induction at the molecular
and cellular level, immune regulation and interactions between the immune system
and stem cell derived tissues.    She is a Fellow of The Academy of Medical
Sciences and received a Royal Society Wolfson Merit Award for research
excellence.  Professor Wood’s research achievements have also been recognized
internationally, including receiving a Gold Medal awarded by The Catalan Society
of Transplantation (2011), The Rose Payne Award from the American Society of
Histocompatibility and Immunogenetics (2011), Excellence in Transplantation
Science Award from The Transplantation Society (2012) and the Maharshi Sushruta
Award (2012).  Professor Wood's professional activities include a broad array of
responsibilities both nationally and internationally.  She was President of The
Transplantation Society (2004-2006), leads the Women in Transplantation
initiative, and is an editor of "Transplantation".

About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that
cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and
efficiently. IdeS has been tested for safety and efficacy in numerous in vitro
and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects
was conducted, demonstrating IdeS as efficacious and well tolerated with a
favorable safety profile. During 2014 and 2015, a Phase II clinical trial in
sensitized patients awaiting kidney transplantation has been conducted.
Preliminary data shows that IdeS has very good efficacy in highly sensitized
patients on the kidney transplant waitlist. The study shows that IdeS has the
capacity to make sensitized patients eligible for transplantation by decreasing
HLA antibodies to levels acceptable for transplantation. In addition to
transplantation, IdeS has potential indications within a variety of rare
autoimmune diseases. IdeS is protected by several patents and has been published
in numerous peer review journals.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on May 6, 2015 at 08:00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO and CFO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com

Christian Kjellman, Ph.D
Chief Scientific Officer
Mobile: +46 705 717417

E-mail: christian.kjellman@hansamedical.com

www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.